Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies fo...
Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos")), a clinical stage biopharmaceutical company focused on developing novel therapeutics to add...
Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple onc...
Shake Shack (SHAK) Q1 review: growth driven by new stores, not demand. Guidance cut, valuation risk, high short interest.
Wells Fargo analyst Constantine Lednev initiates coverage on MDU Resources Group (NYSE:MDU) with a Overweight rating and announces Price Target of ...
Big banks are set to report booming Q2 revenue as the SpaceX IPO, Iran war volatility and a rebound in commercial lending fuel Wall Street's "sweet sp...
Xometry (XMTR) combines 433% EPS growth with a perfect technical rating and a defined breakout setup near $96.53, offering a compelling high-growth mo...
Baird analyst David Koning maintains Circle Internet Group (NYSE:CRCL) with a Outperform and lowers the price target from $138 to $100.
https://www.halliburton.com/en/about-us/press-release/halliburton-winhals-integrated-drilling-completions-contract-granmorgu-suriname-total-energies
Equity LifeStyle Properties (ELS) looks like a buy for durable income and downside protection.
Arbutus (ABUS) looks stronger after Moderna validates its LNP patents, with imdusiran showing durable viral control and a solid runwayâread now.
WILMINGTON, Del., July 13, 2026--Phase 1/2 Multidose Data for VGA039 (Latarcibart) Show Substantial Bleed Reductions in Patients with all Von Willebra...
Keybanc analyst Jeffrey D. Hammond maintains Helios Technologies (NYSE:HLIO) with a Overweight and raises the price target from $85 to $95.
SpaceX, Alibaba's and Nvidia have been highlighted in this Investment Ideas article.
Wells Fargo analyst Constantine Lednev initiates coverage on Atmos Energy (NYSE:ATO) with a Overweight rating and announces Price Target of $200.
Major hotel brands are growing through asset-light models, while property owners face mounting financial pressures.
Baird analyst Eric Coldwell maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $232 to $236.
The group's fortunes come down to a short list of numbers -- and interest rates sit right at the top.
UMH.PR.D preferred stock yields ~7.4% at a discount to par, with strong dividend coverage and housing tailwinds.
Butler National is a strong buy due to aerospace growth, margin expansion & 19%â54% upside despite rotation risks and uplisting delays. For more on ...
Loading...